Secukinumab ELISA Kit,96T,DS856058-96T,Abinscience

PRINCIPLE OF THE ASSAY This assay employs the quantitative indirect enzyme immunoassay technique. Recombinant Human IL17A has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any Secukinumab present is bound by the immobilized protein. After washing away any unbound substances, abiotin-labeled Mouse Anti-Human IgG antibody is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Secukinumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Stability and Storage	When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃.
Detection method	Colorimetric
Sample type	Plasma, Serum
Assay type	Quantitative
Sensitivity	715.94 ng/mL.
Range	937.5 - 15,000 ng/mL
Recovery	80-120%
Background	Secukinumab (Cosentyx) is a fully human IgG1/κ-class monoclonal antibody (mAb) composed of 215 light chain amino acids and 457 heavy chain amino acids. It was discovered and developed by Novartis with the developmental name AIN457, for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. It is produced in Chinese Hamster Ovary (CHO) cells using recombinant DNA technology.
Alternative Names	AIN457, CAS: 1229022-83-6
Shipping	2-8 ℃
Specifications	Secukinumab
Note	For Research Use Only.